Related Experiment Video
Updated: Aug 17, 2026

Targeting Biofilm Associated Staphylococcus aureus Using Resazurin Based Drug-susceptibility Assay
Published on: May 5, 2016
Linezolid for the treatment of a heteroresistant Staphylococcus aureus shunt infection
Aaron M Cook1, Christian N Ramsey, Craig A Martin
1University of Kentucky Chandler Medical Center, Lexington, KY, USA. amcook0@email.uky.edu
Abstract:
The emergence of multidrug-resistant bacteria as the cause of ventriculoperitoneal shunt infections is a disconcerting phenomenon that often requires the use of alternative antimicrobials due to resistance against commonly used agents. The following is a case report describing the successful treatment of a ventriculoperitoneal shunt infection caused by a heteroresistant strain of Staphylococcus aureus with linezolid. Linezolid may have utility in treating pediatric CNS infections due to its tolerability, excellent blood-brain barrier penetration, and activity against multiple resistant Gram-positive organisms such as S. aureus, vancomycin-resistant Enterococcus faecium and Streptococcus pneumoniae.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Staphylococcal Skin Infections
Mechanism of Antibiotic Resistance in MRSA
Acute Pyelonephritis II: Diagnostic Studies and Management
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Antibiotic Selection